Related Experiment Video
Updated: Aug 7, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Drug insight: Clopidogrel nonresponsiveness
Paul A Gurbel1, Udaya S Tantry
1Sinai Center for Thrombosis Research, Baltimore, MD 21215, USA. pgurbel@lifebridgehealth.org
Insights
Clopidogrel nonresponsiveness contributes to ischemic events despite dual antiplatelet therapy. Understanding variability in drug absorption, metabolism, and interactions is key to overcoming resistance and improving patient outcomes.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis
Background:
- Platelet reactivity influences atherothrombosis and ischemic events.
- Dual antiplatelet therapy with clopidogrel and aspirin is standard for acute coronary syndromes and percutaneous coronary intervention.
- Despite benefits, stent thrombosis and other ischemic events persist, partly due to clopidogrel nonresponsiveness.
Purpose of the Study:
- To review clopidogrel response variability and nonresponsiveness.
- To explore mechanisms underlying nonresponsiveness to clopidogrel.
- To discuss strategies for overcoming clopidogrel resistance.
Main Methods:
- Literature review of studies on clopidogrel response and nonresponsiveness.
- Analysis of factors contributing to variability in drug efficacy.
- Synthesis of current research on antiplatelet treatment.
Main Results:
- Nonresponsiveness to clopidogrel is linked to factors like absorption, metabolism, drug interactions, and genetic polymorphisms.
- These factors impact the conversion of clopidogrel to its active metabolite and its antiplatelet effect.
- Existing therapeutic strategies may not fully address clopidogrel resistance in all patients.
Conclusions:
- Clopidogrel nonresponsiveness is a significant clinical issue.
- Addressing variability in drug response is crucial for preventing ischemic events.
- Optimizing antiplatelet therapy may involve dose adjustments or alternative P2Y12 inhibitors.
Abstract:
Platelet reactivity to agonists and subsequent activation are important factors that affect the development of atherothrombosis and resultant ischemic events. Pharmacologic intervention with clopidogrel and aspirin during acute coronary syndromes and percutaneous coronary intervention is considered the gold standard for attenuating platelet activation and aggregation. Despite significant benefits reported with dual antiplatelet treatment in major clinical trials, the occurrence of adverse ischemic events, including stent thrombosis, remains a serious clinical problem. Nonresponsiveness, also called resistance, to current clopidogrel regimens might play a part in the occurrence of ischemic events. Various mechanisms have been implicated in nonresponsiveness to clopidogrel, including variability in intestinal absorption and hepatic conversion to the active metabolite, drug-drug interactions and receptor polymorphisms. Increased loading and maintenance doses and the use of new and more-potent P2Y12-receptor blockers might overcome the phenomenon of clopidogrel nonresponsiveness. The aim of this article is to provide a comprehensive and current review of clopidogrel response variability and nonresponsiveness.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Drug toxicity: Idiosyncratic Reactions
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Factors Affecting Drug Response: Overview
